Prostate cancer
RecruitingStudy of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery
Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery
- Disease:Prostate cancer
- Substances:Lutetium (177LU) vipivotide tetraxetan
Germany- Participants:18–64 years · 65+ years
- Substances:Lutetium (177LU) vipivotide tetraxetan
- Sponsor:Universitaetsklinikum Essen AöR









